TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02722941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panobinostat
Description: Maintenance therapy dosing as outlined in Cohorts A and B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panobinostat
Description: Maintenance therapy dosing as outlined in Cohorts A and B.
Study: NCT04184102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: The intervention group received pre-surgery education and training on therapeutic exercises in addition to the routine hospital care. The educational material was developed by the principal investigator (PI) and included a power point and a booklet with instructions on the exercises as well as information about the surgery and what to expect after the surgery. The educational material was based on previous research and adopted to our population after consultation with a panel of experts including two nurses and three physicians. Eligible women were approached while waiting for their appointment with their surgeon. If they showed interest in participating they signed a consent form. The PI explained the study and what is involved in participating including the weekly phone calls for women in the intervention group. Participants were told that they will visited at home by the PI to assess their ROM and to fill out a questionnaire.
Study: NCT01214434

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bland emollient
Description: Eucerin cream twice daily
Study: NCT03357172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Additional bone marrow aspiration before graft, D30, D90, Y1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Before donation
Study: NCT05638711

Intervention type: DEVICE
Intervention: Built-in calculator to calculate Filtration fraction
Description: A calculator built in electronic CVVH prescription system to calculate Filtration fraction
Study: NCT01670851

Intervention type: DEVICE
Intervention: Strattice
Description: Perineal reconstruction and stoma reinforcement with Strattice
Study: NCT02806765

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
Description: 25 micrograms of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol every day for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Placebo in Softgel form
Study: NCT01079793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study: NCT01930734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Dobutamine infusion up to 5mcg/Kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline solution 0.9% Placebo Arm
Study: NCT01459107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased donor hand transplantation
Description: Deceased donor hand is surgically attached to recipient arm's stump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow cell-based therapy & single-drug immunosuppression.
Description: This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
Study: NCT03732768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radspherin
Description: Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
Study: NCT03485729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: 625 mg dordaviprone (ONC201)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: 625 mg dordaviprone (ONC201)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: 625 mg dordaviprone (ONC201)
Study: NCT01719081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacroiliac Joint Injection
Description: Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacroiliac Joint Injection
Description: Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
Study: NCT03949582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test food containing different types of dietary protein
Description: The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test food containing different types of dietary protein
Description: The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum
Study: NCT02299908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP block with Bupivacaine at 0.25%
Description: Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline solution
Description: Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
Study: NCT04171726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.
Study: NCT01700504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axillary lavage with gentamicin solution
Description: Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axillary lavage with gentamicin solution
Description: Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
Study: NCT02297503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azzalure
Description: Glabellar lines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azzalure
Description: Glabellar lines

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane/Emervel filler
Description: Facial tissue augmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane/Emervel filler
Description: Facial tissue augmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Skinbooster
Description: Facial skin rejuvenation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Skinbooster
Description: Facial skin rejuvenation
Study: NCT04609150

Intervention type: OTHER
Intervention: Bone marrow fat quantification by MRI
Description: Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty
Study: NCT02688036

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated concurrent chemoradiotherapy
Description: For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventionally fractionated concurrent chemoradiotherapy
Description: For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
Study: NCT04786886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIrtual Reality Visual Field Exam
Description: Virtual reality visual field exam will be administered using the virtual reality headset. Exams can take up to 20 minutes.
Study: NCT04266990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Planned Sweat collection
Description: Four times a day at fixed time points (9:30, 11:30, 13:30, 15:30), a researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spontaneous Sweat collection
Description: As the patient will be under continuous monitoring, sweat and saliva samples will be also collected during and/or right after a seizure occurs if the volunteer is not holding a gauze at that time. The sweat samples will be collected by the researcher by applying a sterile gauze to the patients hands, either during or immediately following a seizure during 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy volunteers sweat collection
Description: A researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher. The healthy samples will be collected on the same floor of Ghent University Hospital and as close as possible to where patients reside
Study: NCT05701943

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based
Description: During the home-based intervention, aerobic training was performed using body weight exercises such as jumping jacks, standing box, side shift with floor touch, high knees, half burpee, and hook box (Borrega-Mouquinho et al., 2021).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based
Description: During the home-based intervention, aerobic training was performed using body weight exercises such as jumping jacks, standing box, side shift with floor touch, high knees, half burpee, and hook box (Borrega-Mouquinho et al., 2021).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gym-Based
Description: During the gym-based intervention, aerobic training was performed on cycle ergometers (Star Trac Spinner Blade ION 7220, Vancouver, WA).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gym-Based
Description: During the gym-based intervention, aerobic training was performed on cycle ergometers (Star Trac Spinner Blade ION 7220, Vancouver, WA).
Study: NCT02728518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Amikacin
Description: 400mg twice daily nebulized amikacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Amikacin
Description: 20mg/kg once daily intravenous amikacin
Study: NCT03972293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study behavioral change mobile notification
Description: The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications have 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. To increase the category of interest, the notifications use two types of messages: life insights and tips. Life insights provide participants information on their historical data (for a given category) in order to help them self-monitor. Tips are non-data based notifications which provide general advice for improving the category of interest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app
Description: The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app
Description: The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
Study: NCT02977975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw sauerkraut
Description: Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.

Intervention type: OTHER
Group type: OTHER
Intervention: Pasteurized sauerkraut
Description: Sauerkraut without live bacteria.
Study: NCT03344614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed combined with apatinib
Description: raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles
Study: NCT05969106

Intervention type: DEVICE
Intervention: Tandem Control-IQ
Description: AID-system
Study: NCT03357172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell sample
Description: Allogeneic hematopoietic stem cell sample
Study: NCT02976844

Intervention type: PROCEDURE
Intervention: Positive end-expiratory Pressure
Description: Positive end-expiratory pressure will be used during mechanical ventilation.
Study: NCT05969106

Intervention type: DEVICE
Intervention: Tandem Control-IQ
Description: AID-system

Intervention type: DEVICE
Intervention: Tandem Control-IQ
Description: AID-system
Study: NCT03658330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + Naltrexone
Description: Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
Study: NCT04675411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart care
Description: Home based nursing intervention with smart assisted technology

Intervention type: DEVICE
Group type: OTHER
Intervention: usual care
Description: Routine hospital care with only in-hospital rehabilitation
Study: NCT01595750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast 500
Description: Roflumilast 500 mcg , 12 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500 mcg , 12 weeks of treatment
Study: NCT01847144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide 80mg OD
Description: Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg OD
Description: Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
Study: NCT02528669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RX Navigait
Description: The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
Study: NCT05493956

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: Radiation dose of 54 Gy will be given alongwith concurrent capecitabine

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiation
Description: Radiation dose of 54 Gy will be given alongwith concurrent capecitabine
Study: NCT00325442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral treprostinil (UT-15C) sustained release tablets
Description: UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
Study: NCT04466683

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose radiation 35 cGy
Description: A dose of 35 cGy of whole thorax irradiation will be delivered at a single timepoint

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High dose radiation 100 cGy
Description: A dose of 100 cGy of whole thorax irradiation will be delivered at a single timepoint
Study: NCT02909166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aliskiren
Study: NCT04994821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulator (tDCS)
Description: Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulator (tDCS)
Description: Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulator (tDCS)
Description: Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal
Description: Emotion regulation therapy
Study: NCT01288040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split Belt treadmill
Description: A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
Study: NCT02411812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herbst appliance with skeletal anchorage
Description: Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst appliance with dental anchorage
Description: Group treated with the conventional Herbst appliance with dental anchorage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin-Block appliance
Description: Group treated with Twin-Block appliance
Study: NCT06137521

Intervention type: PROCEDURE
Intervention: Coronary angiography

Intervention type: PROCEDURE
Intervention: Coronary angiography
Study: NCT03610971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Description: The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
Study: NCT03762850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sparsentan
Description: Target dose of 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sparsentan
Description: Target dose of 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sparsentan
Description: Target dose of 400 mg daily
Study: NCT01837043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin Inhibitor
Study: NCT04066543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: The modified Seldinger puncture was used to puncture the cutaneous-femoral artery, insert the catheter and perform hepatic artery angiography. The location, morphology and blood supply of liver tissue lesions were comprehensively understood. The use of chemotherapeutic drugs and the dosage of iodized oil as the embolic agent were determined according to the general situation. The catheter was injected into the supply vessel of the tumor, and 5-FU and adriamycin were injected according to the situation. The embolic agent was injected with iodized oil as carrier, mixed with chemotherapeutic drugs at the same time, and then assisted with gelatin sponge for embolization. Antiemetic drugs were given before treatment and hepatoprotective drugs were given after operation. Until the disease progresses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE
Description: The modified Seldinger puncture was used to puncture the cutaneous-femoral artery, insert the catheter and perform hepatic artery angiography. The location, morphology and blood supply of liver tissue lesions were comprehensively understood. The use of chemotherapeutic drugs and the dosage of iodized oil as the embolic agent were determined according to the general situation. The catheter was injected into the supply vessel of the tumor, and 5-FU and adriamycin were injected according to the situation. The embolic agent was injected with iodized oil as carrier, mixed with chemotherapeutic drugs at the same time, and then assisted with gelatin sponge for embolization. Antiemetic drugs were given before treatment and hepatoprotective drugs were given after operation. Until the disease progresses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
Study: NCT02022514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mononuclear cells from autologous bone marrow
Description: Mononuclear bone marrow cells autologous intracoronary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medical treatment